Question 1

What has hCG actually been compared against?

Accepted Answer

Four kinds of comparison appear in the research behind this page, and all of them sit inside a clinic. The largest is a network meta-analysis comparing hCG trigger with GnRH agonist trigger, dual trigger, and double trigger in twelve randomised trials. A network meta-analysis pools trials that each tested two options, so that options never tested directly can still be ranked through shared comparators. The second is a cohort that set a small hCG dose against freezing every embryo. The third is luteal support in IVF, where hCG was set against progesterone, and the fourth is undescended testicles in boys, where hCG was weighed against a releasing hormone delivered by nasal spray. Not one of those comparisons involves growth hormone, testosterone replacement, muscle or weight. The questions people bring to this page were simply not the questions these studies were built to ask.

Question 2

Is hCG better than TRT?

Accepted Answer

No study among the research behind this page set the two against each other, so there is no result to rank. What the record does show is that they answer different problems. A 2020 review defines male hypogonadism as an inadequate testosterone production, and notes that combined forms of the condition can also occur. Testosterone replacement supplies the end hormone directly. hCG instead asks the testes to make it, which only works if the testes can still answer. In the stimulation test in men with spinal cord injury, the authors concluded the work confirmed the absence of primary testicular dysfunction in that group. Their findings pointed instead to a secondary testicular dysfunction, meaning a fault upstream of the testes, in most of those men with low testosterone. That is the logic that decides between the two in a clinic. Better is not the right word for it, because the choice turns on where the fault sits rather than on which hormone is stronger.

Question 3

Is hCG the same as HGH?

Accepted Answer

No, and the near-identical letters cause real confusion. HGH is human growth hormone, made by the pituitary gland. hCG is a pregnancy hormone, and the word gonadotropin in its name means a hormone that acts on the ovaries or testes. The placenta happens to make both kinds of hormone, which makes a useful way to see them apart. A 2025 review lists the placental hormones as including human chorionic gonadotropin, human placental lactogen, and placental growth hormone, among others. It describes that group as essential for pregnancy maintenance, fetal growth, and metabolic adaptation. So even inside one organ, hCG and a growth hormone are listed as separate hormones with separate jobs. What is documented about growth hormone itself, including its approvals, is covered on the HGH overview, and none of it transfers to hCG.

Question 4

Can I take hCG with HGH?

Accepted Answer

No study among the research behind this page gave the two together, so nothing about combining them is measured here. That is worth separating from the question of whether anyone does it, which a study cannot answer. The nearest relevant evidence is the shape of the clinical toolkit. The 2020 review of low testosterone in men gathers evidence on testosterone formulations, human chorionic gonadotropin, selective estrogen receptor modulators and aromatase inhibitors. Growth hormone is not on that list of options for male hormone problems. So a combination of hCG and HGH does not come from the clinical literature on either hormone, and what it would do is not recorded anywhere a reader can check. That is not the same as a finding that the pairing causes harm, and it is not a finding that it is harmless either. Each has its own harm record, and those records were built separately. What is documented about hCG on its own is set out on the HCG safety page, and the growth hormone record is on the HGH safety page.

Question 5

How does an hCG trigger compare with a GnRH agonist trigger?

Accepted Answer

On pregnancy, closely. A trigger is the timed injection that ripens eggs before collection, and a GnRH agonist works instead through the brain signal one step higher up the same chain. For clinical pregnancy, the pooled risk ratio was 1.13 for hCG against the GnRH agonist trigger, with a confidence interval of 0.80 to 1.60. That interval spans 1, so the trials could not separate the two on pregnancy. The authors concluded that there is no evidence to suggest that using GnRH agonist, dual, or double protocols is superior to hCG trigger in improving clinical pregnancy rates. They also observed no significant differences in the number of oocytes retrieved or in miscarriage rates among the protocols. Where the two differ is ovarian hyperstimulation, and that comparison, with its wide interval, is set out on the HCG safety page rather than repeated here.

Question 6

Do combined triggers beat hCG alone?

Accepted Answer

Possibly on live births, and the authors are careful about how far that goes. Dual trigger demonstrated the highest Surface Under the Cumulative Ranking, at 85.1%, which the authors read as superior efficacy for clinical pregnancy. That statistic is a ranking across the network rather than a measured gap, and it is not the same as a significant difference between two arms. For live birth, the risk ratio was 1.31 for dual against hCG trigger, with an interval of 1.00 to 1.70. The authors add that although live birth may benefit from dual trigger, results are limited by available RCTs. An interval that touches 1.00 at its lower boundary sits precisely on the line of no difference, so the defensible reading is a modest lean toward the combination on live births, supported by relatively few trials, with the hyperstimulation consequences of the combination left entirely unreported.

Question 7

Does a small hCG dose after egg collection match freezing every embryo?

Accepted Answer

In one clinic's records it did, on the outcomes that were counted. The cohort compared a GnRH agonist trigger plus 1500 IU of hCG with a freeze-all approach in high responder women, and baseline characteristics were similar between the groups. Clinical pregnancy rates were 45.9% in the hCG group and 43.8% in the freeze-all group. Live birth rates were 40.5% and 41.7%, which the authors judged comparable between groups. Read the design before the numbers: this was a retrospective cohort, meaning existing records were compared after the fact, and nobody was randomised into either group. Similar baseline characteristics help, but they are not the same as the balance that randomisation produces. The one clear difference between the arms was hyperstimulation, which occurred only in the hCG group and is covered on the safety page.

Question 8

Is hCG better than progesterone for luteal support?

Accepted Answer

In the controlled studies a 2008 review gathered, neither came out ahead. Luteal support means hormone given after egg collection to hold up the womb lining while an embryo implants. The review found that in most major controlled and randomized studies there are no significant differences in success rates between progesterone alone, progesterone with estradiol, progesterone with hCG, and hCG alone. It adds that success rates seem similar with intramuscular and vaginal progesterone, with patient preference for the vaginal route. So four ways of giving luteal support performed alike on success. Where they differ is in what else they bring, and for hCG that includes the hyperstimulation risk tied to it elsewhere in this record. A tie on pregnancy is not a tie on everything else that matters to the woman receiving it.

Question 9

hCG or LHRH for undescended testicles?

Accepted Answer

The older reviews compared them, and the stronger finding favours using both. LHRH is luteinising hormone releasing hormone, the brain signal that sits upstream of the testes, and it can be given by nasal spray. A 1979 review set the bar for the spray at matching hCG, saying LH-RH would first have to obtain the same success rate as HCG in larger series. A 1995 review reports that a combination of the two hormones has had a greater effect in inducing testicular descent compared to single hormone treatment. The same review favours hormonal treatment in the first year of life, since it can at the same time induce scrotal descent and substitute postnatal gonadotropin insufficiency. Both are review statements rather than trial results, and neither gives numbers for the combination. They describe infants with a specific condition, which is a long way from an adult man.

Question 10

How does low-dose hCG compare for a thin womb lining?

Accepted Answer

It sits on a long list of options that share one weakness. A thin endometrium, the womb lining, can stop an embryo implanting, and many approaches have been tried to thicken it. A 2022 review says inconsistency in the improvement of endometrial thickness is a common limitation of therapies including low-dose human chorionic gonadotropin during endometrial preparation. The same list includes acupuncture, aspirin and extended estrogen therapy, which tells you how unsettled the field is. The authors set cell therapy, including stem cells and platelet-rich plasma, against that list as a proposed alternative. That is a review grouping options by a shared weakness, which is not the same as a trial ranking them. hCG's place on the list says it has been tried, and that results were inconsistent.

Question 11

Has hCG been compared with kisspeptin?

Accepted Answer

Not in the trigger trials pooled here. The 2025 analysis set out to compare efficacy and safety of hCG, GnRH agonist, dual, and double triggers in predicted healthy responders. Kisspeptin is not one of those four. It is a brain hormone that sits at the top of the same reproductive chain, and it has been studied as a trigger in its own right. That work belongs to a separate literature, and what it compares kisspeptin against, including hCG, is taken apart on the Kisspeptin comparison page. The distinction matters for anyone reading claims online. A statement that kisspeptin outperforms hCG comes from research on kisspeptin, and nothing in the hCG trial record behind this page tested it.

Question 12

How does the hCG diet compare with other weight-loss agents?

Accepted Answer

Only as an entry on a toxicology list, which is not a comparison of effect. The 2012 review placed human chorionic gonadotropin hormone in a group that ran through fenfluramine, sibutramine, thyroid hormone, orlistat and cannabinoid antagonists. The authors chose topics they thought most historically significant as well as pertinent to the practice of medical toxicology today. So the list groups agents by their history of causing harm rather than by how much weight anyone lost. No study among the research behind this page measured weight in anyone given hCG, which leaves nothing to set beside the trial record of the newer weight-loss compounds. Readers weighing hCG against those compounds can see what was actually measured for one of them on the Semaglutide overview.

Question 13

What has hCG been combined with outside human medicine?

Accepted Answer

Breeding programmes use it, and one of them shows how a combination can behave unlike its parts. A 1992 review describes inducing heat in pigs with pregnant mare serum gonadotropin and human chorionic gonadotropin, and using hCG to control the onset of ovulation. In yellow catfish, a population with a defective reproductive duct showed high mortality after being induced with a combination of hCG, LHRH and domperidone. Adding carp pituitary extract to the same three hormones efficiently induced spawning and reduced mortality in that animal study. Fish are not people, and nobody should read a dose into this. The point is narrower. A blend's effect was measured as a blend, and it differed from what its parts implied.

Question 14

What would a fair comparison of hCG need?

Accepted Answer

It would need the same people, randomised, measured on the outcome being argued about. The fertility record comes closest, and its authors still ask for more. The 2025 analysis concludes that larger, multicenter trials are needed for further evaluation of live birth rates and understanding of long-term outcomes. For the comparisons people actually search for, nothing of that kind is on file here. A fair test of hCG against testosterone replacement would randomise men with an identical category of hormone fault and follow testosterone, fertility and documented harm over several months. A fair test of hCG with growth hormone would need a reason to combine them first, and the clinical literature behind this page does not supply one. Until then, each is described by what it was studied for, which tells a reader what each was meant to do rather than which one wins.

HCG comparisons and stacks